29.01.2021 13:07
The Swiss-Dutch clinical-stage biotech startup, Pharvaris, developing small molecule therapies for rare diseases, reports that during its phase I study lead candidate PHA121 was well tolerated. As reported by Renaissance Capital, Pharvaris has filed for an initial public offering with the SEC to raise up to $100 million.